The new data supports the continued marketing of BioNTech's breast cancer subtyping assay as an alternative to IHC, and suggests added value for the test in assessing Ki-67 specifically.
The two partners hope to start a Phase I combination trial pairing Genentech's anti-PDL1 cancer immunotherapy Tecentriq with vaccines developed using BioNTech's IVAC Mutanome.
The deal will leverage BioNTech's IVAC Mutanome platform, which uses next-generation sequencing to identify targets for personalized mRNA-based vaccines.
The diagnostic, a real-time PCR kit for breast cancer stratification, is being reviewed under a special process for the approval of innovative products.
Newsweek discusses the privacy issues raised by digital medicine.
A group of statisticians want to eliminate researchers' reliance on 'statistical significance,' according to NPR.
In Nature this week: genetic analysis of Anatolian farmers, cotton genome analysis, and more.
Matt Hancock, the UK health secretary, is calling for the swift rollout of predictive genetic tests, the Guardian reports.